NeuroDerm Ltd., of Ness Ziona, Israel, received a $1 million grant from the Michael J. Fox Foundation for Parkinson's Research to support the next clinical study with ND0611, a dermal patch to treat Parkinson's disease

Epitomics Inc., of Burlingame, Calif., plans to distribute a panel of LRRK2 monoclonal antibodies jointly developed with the Michael J. Fox Foundation for Parkinson's Research to the entire Parkinson's disease research community at a low cost to help advance therapeutic development efforts

Addex Pharmaceuticals Ltd., of Geneva, was awarded a $900,000 grant from the Michael J. Fox Foundation to help fund a Phase II study of ADX48621, a metabotropic glutamate receptor 5 negative allosteric modulator, for the treatment of Parkinson's disease levodopa-induced dyskinesia

Addex Pharmaceuticals Ltd., of Geneva, was awarded a $900,000 grant from the Michael J. Fox Foundation to help fund a Phase II study of ADX48621 , a metabotropic glutamate receptor 5 negative allosteric modulator, for the treatment of Parkinson's disease levodopa-induced dyskinesia

The firm has been studying tafamidis in amyloid cardiomyopathy and has earlier candidates such as a cystic fibrosis drug being funded through a $22 million collaboration with the Cystic Fibrosis Foundation and a Parkinson's disease drug supported by a small grant from the Michael J. Fox Foundation. (See BioWorld Today, Aug. 14, 2007.) "We see this deal as proof that the work we've done is high quality, from the bench to the regulatory process," Labaudiniere said

The study was conducted in collaboration with scientists at Mayo Clinic and the Parkinson's Institute, and funded by a LEAPS (Linked Efforts to Accelerate Parkinson's Solutions) award from The Michael J. Fox Foundation for Parkinson's Research

of Health used to demonstrate the feasi- (FSE:BII) bility of using the company's Pressure Cycling Technology to develop an automated sample preparation procedure for the extraction and purification of nucleic acids from a variety of biological samples in a single processing step (3/9) Proneuron Michael J. Fox $0.43 Grant Grant to examine PN277's Biotechnologies Foundation for ability to prevent degeneration Inc.* Parkinson's Research of

Michael J. Fox Foundation for Parkinson's Research $2.1 Grants For preclinical projects focused on neuroprotective therapeutic targets for Parkinson's disease, including Carmot, Opsona and Intermed's focus on inflammation and oxidative stress, FoldRx and Pfizer's focus on alpha-synuclein, plus Envivo's program looking at inhibitors of histone deacetylase (1/20) Celsion Corp. (CLSN) Center for Translational Molecular Medicine ND Grant For magnetic resonance imaging- guided high intensity

WSBI had managed to secure some seed capital and grant money early on, said Michael J. Reilly, co-founder, president and CEO

The company is also supported by the research charities Association Française contre les Myopathies and the Michael J Fox Foundation, and has received grants from the French government and European Union funding for the Phase III trial of olesoxime in ALS

The company is also supported by the research charities Association Franaise contre les Myopathies and the Michael J Fox Foundation, and has received grants from the French government and European Union funding for the Phase III trial of olesoxime in ALS

Cortex Pharmaceuticals Inc., of Irvine, Calif., received a grant from the Michael J. Fox Foundation for Parkinson's Research to test selected compounds from its Ampakine platform for their ability to restore brain function in animal models of Parkinson's disease

Sangamo BioSciences Inc., of Richmond, Calif., was awarded a second round of funding by the Michael J. Fox Foundation for Parkinson's Research to support studies in nonhuman primates for the development of a ZFP therapeutic in Parkinson's disease

Also last week, the Michael J. Fox Foundation for Parkinson's Research granted to Ceregene Inc., of San Diego, $2.5 million to support Phase II testing of CERE-120, a gene therapy that brings neurturin to dying dopamine brain neurons

The Michael J. Fox Foundation for Parkinson's Research, of New York, granted $4.6 million in awards to support work on two programs targeting neurotrophic factor therapies in Parkinson's disease

FoldRx expects to select a clinical candidate for the program by the end of next year. (See BioWorld Today, Aug. 14, 2007.) FoldRx also has done some research in Parkinson's disease under a small grant from the Michael J. Fox Foundation

Amarantus Therapeutics Inc., of Sunnyvale, Calif., said it has received a $350,000 research grant from The Michael J. Fox Foundation for Parkinson's Research to study the efficacy of mesencephalic astrocyte-derived neurotrophic factor (MANF), a highly potent, neurotrophic factor currently in preclinical development for the treatment of Parkinson's disease

Amarantus Therapeutics Inc., of Sunnyvale, Calif., and Biodesy LLC, of Burlingame, Calif., were among the recipients of grant money from The Michael J. Fox Foundation for Parkinson's Research awarded during the first quarter

Michael J. Simms ALEXZA PHARMACTCLS INC 315 88 403 46 David W. Keiser ALEXION PHARMACEUTICALS INC 400 400 47 Troy A. Barring NORTH AMERICAN SCIENTIFIC 284 116 399 48 James V. Caruso ALLOS THERAPEUTICS INC 396 396 49 Thomas A. Pitler NEUROGEN CORP 274 118 392 50 Kimberly J. Popovits GENOMIC HEALTH INC 380 380 51 Stewart Craig STEMCELLS INC 275 105 380 52 Timothy G. Healey AMAG PHARMACEUTICALS INC 280 99 379 53 Peter S. Lawrence ARQULE INC 374